Opinion
Video
Author(s):
Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 and PIK3CA mutations.
Clinical Brief: EMERALD Trial Insights for ESR1-Mutant Breast Cancer
Main Discussion Topics:
Key Points for Physicians:
The EMERALD trial established that patient selection based on endocrine sensitivity duration, rather than just mutation presence, optimizes treatment outcomes with elacestrant.